A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

It's in Novo Nordisk's best interest to produce more winning ... which acts as a drug delivery system, with the plan being for ambient cellular machinery within the patient's body to handle ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. self-regulatory body found fault with Novo’s support for U.K pharmacy chains’ weight management services, leading its ...

Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...

The CEO of Novo Nordisk wouldn’t commit to lowering the ... Ozempic for diabetes is covered by 99 percent of commercial plans, he said, as well as Medicare and Medicaid. But coverage of Wegovy ...

Novo Nordisk's chief scientific officer Marcus Schindler called it "a new and innovative way of collaborating", with the current plan that it will generate between three and five research ...

Novo Nordisk (NVO) CEO Lars Jørgensen told lawmakers Tuesday he was willing to sit down with pharmacy benefit managers (PBMs) to discuss a lower price for Wegovy and Ozempic, the company's ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Drugmaker is pressed to cut prices for its blockbuster diabetes and obesity drugs The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday ...